Hemorrhagic Transformation After Tissue Plasminogen Activator Treatment in Acute Ischemic Stroke

 Useless, 'progress' is NOT GOOD ENOUGH. What are the protocols needed to prevent this from happening and then GET TO 100% RECOVERY?

Hemorrhagic Transformation After Tissue Plasminogen Activator Treatment in Acute Ischemic Stroke

• Chengli Liu,
• Jie Xie,
• Shanshan Sun,
• Hui Li,
• Tianyu Li,
• Chao Jiang,
• Xuemei Chen,
• Junmin Wang,
• Anh Le,
• Jiarui Wang,
• Zhanfei Li,
• Jian Wang &
• Wei Wang 

Cellular and Molecular Neurobiology (2020)Cite this article

• 5 Accesses

• 3 Altmetric

• Metrics details

Abstract

Hemorrhagic transformation (HT) is a common(What is your definition of common?) complication after thrombolysis with recombinant tissue-type plasminogen activator (rt-PA) in ischemic stroke. In this article, recent research progress of HT in vivo and in vitro studies was reviewed. We have discussed new potential mechanisms and possible experimental models of HT development, as well as possible biomarkers and treatment methods. Meanwhile, we compared and analyzed rodent models, large animal models and in vitro BBB models of HT, and the limitations of these models were discussed. The molecular mechanism of HT was investigated in terms of BBB disruption, rt-PA neurotoxicity and the effect of neuroinflammation, matrix metalloproteinases, reactive oxygen species. The clinical features to predict HT were represented including blood biomarkers and clinical factors. Recent progress in neuroprotective strategies to improve HT after stroke treated with rt-PA is outlined. Further efforts need to be made to reduce the risk of HT after rt-PA therapy and improve the clinical prognosis of patients with ischemic stroke.

This is a preview of subscription content, log in to check access.